Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply

Affiliations

¹ Velindre Cancer Centre, Cardiff, UK. Electronic address: robert.hugh.jones@wales.nhs.uk.
² Centre for Trials Research, Cardiff University, Cardiff, UK.
³ Oncology R&D, AstraZeneca, Cambridge, UK.
⁴ Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.

Comment

Robert H Jones et al. Lancet Oncol. 2020 May.

. 2020 May;21(5):e234.

doi: 10.1016/S1470-2045(20)30237-0.

¹ Velindre Cancer Centre, Cardiff, UK. Electronic address: robert.hugh.jones@wales.nhs.uk.
² Centre for Trials Research, Cardiff University, Cardiff, UK.
³ Oncology R&D, AstraZeneca, Cambridge, UK.
⁴ Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.

No abstract available

Comment on

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Jones RH, et al. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5. Lancet Oncol. 2020. PMID: 32035020 Free PMC article. Clinical Trial.
Fulvestrant plus capivasertib for metastatic breast cancer.
Dekker TJA. Dekker TJA. Lancet Oncol. 2020 May;21(5):e232. doi: 10.1016/S1470-2045(20)30153-4. Lancet Oncol. 2020. PMID: 32359497 No abstract available.
Fulvestrant plus capivasertib for metastatic breast cancer.
Ludmir EB, McCaw ZR, Kim DH, Tian L, Wei LJ. Ludmir EB, et al. Lancet Oncol. 2020 May;21(5):e233. doi: 10.1016/S1470-2045(20)30228-X. Lancet Oncol. 2020. PMID: 32359498 No abstract available.